Announcements Trials

Browse Landscape Eligibility

Clinical Trials

2 trials

Recent Start date Enrollment

Approved for marketing × Breast Neoplasms × abemaciclib × Clear all

Status

Recruiting 33 Active not recruiting 21 Completed 12 Terminated 9 Not yet recruiting 7 Withdrawn 4 Unknown 3 Approved for marketing 2

Sponsor Class

Study Type

Expanded_access 2

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2

Interventions

abemaciclib 2 zenocutuzumab 1 selpercatinib 1 eribulin 1 Lapatinib 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03763604 2024-12-16

Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Eli Lilly and Company

Approved for marketing

Breast Neoplasms

NCT02792725 2017-10-31

Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Eli Lilly and Company

Approved for marketing

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡